Enveda
Enveda uses AI to discover biologically active molecules from nature and develop them into small-molecule medicines for inflammatory and metabolic diseases.
$311MSeries E
ParticipantTR
T. Rowe Price Investment Management
Activity from announced rounds
Activity in this selectionUnited States
- Rounds participated in
- 5
- Confirmed lead rounds
- 0 4 roles undisclosed
- New companies
- 5 First participation on record · 0 follow-on
- Funding in participating rounds
- $1.5B 5 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
5 in this selectionOllin Biosciences
Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD
$330MSeries B
Role not disclosedSiFive
SiFive licenses RISC-V processor intellectual property for custom computing chips, including high-performance data-centre designs.
$400MSeries G
Role not disclosedCellares
Develops automated cell therapy manufacturing platforms
$257MSeries D
Role not disclosedMirador Therapeutics
Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases
$250MSeries B
Role not disclosed